CD BioSciences is a biotechnology company dedicated to promoting the high resolution 3Dmicroflu™ 3D bioprinting technology platform and high quality customised bioinks that can be applied to 3D printing organ and tissue micro-models. 3Dmicroflu™ technology platform can be used for the in vitro construction of tumour models in disease models that can better match the tumour microenvironment. This has important implications for the study of complex mechanisms of tumour diseases. The 3D bioprinting experts from CD BioSciences are always looking forward to your inquiries and orders.
The tumour is a new organism formed when a cell in a local tissue loses the normal regulation of its growth at the genetic level in response to various carcinogenic factors, resulting in clonal abnormal proliferation. It is generally believed that tumour cells are monoclonal, which means that all the tumour cells in a tumour are descendants of a single mutated cell. Generally tumours are divided into two categories, including benign and malignant, where malignant tumours originating from mesenchymal tissue are collectively known as sarcomas and malignant tumours originating from epithelial tissue are known as cancers.
Fig. 1. Composition of the tumour microenvironment. (Yao, Y, et al., 2016)
The diagram above illustrates the complex composition of the tumour microenvironment. The tumour microenvironment (TME) is the complex environment in which tumour cells survive and develop including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, various signalling molecules and the extracellular matrix (ECM). The immune cells within the microenvironment and the way they are regulated play an important role in tumourigenesis and development. In addition, the tumour microenvironment plays a crucial role in tumour metastasis. Research on tumour mechanisms requires the integration of the tumour and its microenvironment, which cannot be stripped away. This is because they interact and are interconnected in contributing to disease development.
Cancer is currently one of the most important diseases threatening human health. The research on the mechanisms and treatments of tumours has always been a focus area for researchers and is of great importance to human life and health. The current research on tumours has some inherent problems that have prevented major research breakthroughs. On the one hand, traditional two-dimensional tumour models do not truly reflect the complex structure of tumours, as shown on the left in the figure below. On the other hand, tumour models are mostly based on animal models with human tumours, which are not only very different from human structures, but are also not very humanitarian for the animals used for experiments.
Fig. 2. 3Dmicroflu™ for in vitro tumour modelling.
CD BioSciences offers the high resolution 3Dmicroflu™ 3D printing technology platform that can be applied to the construction of in vitro micro-models of tumours and metastatic micro-models of tumours. The tumour models constructed by 3Dmicroflu™ technology platform can realistically and finely reflect the complex tumour structure and simulate the tumour microenvironment. In addition, tumour metastasis and spread are often the main reasons for tumour treatment failure. Malignant tumour cells will autonomously travel from the primary site, through lymphatic channels, blood vessels or body cavities, to other sites and continue to grow. 3Dmicroflu™ allows you to construct tumour metastasis models for the study of pathogenesis and drug screening related to tumour spread. Based on our high-resolution single cell printing technology, different types of tumour models can be constructed in vitro and used for drug screening studies, such as liver cancer models, glioma models, cervical cancer models and ovarian cancer models.
By recreating the complex structure of the tumour environment (including matrix and immune interactions, angiogenesis and ECM remodelling) in vitro with CD BioSciences' technology platform, your work on tumour pathogenesis and the development of personalised oncology drugs will be greatly advanced. If you choose our technology platform, 3Dmicroflu™ will be an important aid in achieving breakthroughs in your oncology disease research.
If you are interested in our high-resolution 3Dmicroflu™ 3D bioprinting technology platform, please contact us now for professional services. All services are available on a 24/7/365 basis.